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| INTRODUCTION
Most cancer mortalities are due to the metastasis of tumor cells to other organs. 1, 2 The lymphatic vasculature is one of major routes for tumor cell dissemination. 3 For many carcinomas such as cutaneous melanoma, the dissemination of tumor cells via lymphatic drainage is the most common route. 4 Therefore, tumor lymphangiogenesis, the formation of new lymphatic vessels (LV) at primary tumor or distant sites, has been regarded as a key prognostic marker for patients with carcinomas. 5 However, lymphangiogenesis in tumors does not always have a significant relationship with LN metastasis. 6, 7 In fact, sentinel LN removal does not necessarily extend the overall survival of patients with melanoma. 8, 9 Moreover, LV collapse and become dysfunctional during tumor progression. 10, 11 Recent studies have revealed the heterogeneity of lymphatic endothelial cells (LEC). In contrast to blood vascular endothelial cells (BEC), LEC have variable extracellular coverage over the lymphatic vasculature. While capillary LEC are attached by filament bundles and then directly anchored to the extracellular matrices, the LEC in precollector vessels are sparsely covered with smooth muscle cells (SMC), but in collector LV they are lined with a basement membrane and a layer of SMC, structurally resembling veins with LEC continuously connected to each other in a "zipper-like" structure. 12 The heterogeneous pattern of gene expression may underlie the distinct structure and specialized function of LV. For example, the lymphatic vessel endothelial hyaluronic acid receptor-1 (LYVE-1), an LEC-specific surface marker, is downregulated in the collecting LV but remains high in lymphatic capillaries, 13 likely mediating the trafficking of leukocytes within LV. 14 Podoplanin (PDPN), another LEC marker, and is lowly expressed in skin lymphatic precollectors, 15 involved in lymphocyte trafficking during skin inflammation. 15 In addition, lymphatic capillaries highly express chemokine CCL21, which guides migration of dendritic cells (DC) toward the LV. 16 Furthermore, LEC in collecting LV express a high level of endothelial nitric oxide synthase (eNOS), 17 which is related to LV contractility and permeability ( Figure 1 ). 18 Due to the heterogeneity in LV structure and gene expression pattern, it can be predicted that the LV in different tissues exhibit variable responses to lymphangiogenic factors. Indeed, single subcutaneous injection of vascular endothelial growth factor (VEGF)-C was enough to induce lymphangiogenesis, 19 while in the central nervous system, injection of VEGF-C into the cisterna magna only caused an increase in the diameter of meningeal LV. 20 Notably, significant differences in the lymphangiogenic response were detected in cornea from several different mouse strains, 21 suggesting that genetic background significantly influences lymphangiogenic response.
Recent studies have shown that the heterogeneity of lymphatic vasculature with organ-specific structural and functional features may be due to the diverse developmental origins of LEC and specializations of lymphatic vasculature to adapt to organ-specific environments and to meet functional requirements during development and physiological processes. The advances of these findings have been covered by excellent recent reviews. [22] [23] [24] In this review, we examine what we know so far about the heterogeneity of tumor lymphangiogenesis in an attempt to understand new functions of lymphangiogenesis in tumor progression. Elucidating the mechanism that causes lymphangiogenesis heterogeneity in solid tumors may provide better insight into the role of lymphangiogenesis in tumor progression and potential implications for tumor treatment.
| STRUCTURAL HETEROGEN EITY OF TUMOR LYMPHANGIOGEN ESIS
Under pathophysiological conditions such as inflammation and tumors, the structural heterogeneity in lymphatic vasculature renders LEC highly multiplex and plastic in response to various injury stimuli.
Consequently, the heterogeneity of tumor lymphangiogenesis appears to be even more severe. 25 
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F I G U R E 1 Structure and molecular features of lymphatic capillaries and collectors. The blind-ended lymphatic capillaries are characterized by button-like intracellular junctions, discontinuous basement membrane, attached by filament bundles, and anchored to the extracellular matrices. Lymphatic capillaries highly expressed lymphatic vessel endothelial hyaluronic acid receptor-1 (LYVE-1), podoplanin and CCL21 to mediate the recruitment of leukocytes. When interstitial pressure increases, the lymph drains from the lymphatic capillaries to precollector and collector lymphatic vessels (LV). Collecting LV have zipper-like intracellular junctions, continuous basement membrane, smooth muscle cell (SMC) coverage and valves that prevent backflow of the lymph. Collecting LV highly express eNOS, which is related to LV contractility and permeability ability. 31 In addition, CD34, a BEC marker, was preferentially expressed in intratumoral LEC of colon, breast, lung and skin tumors. 32 Notably, LEC intercellular junction molecules show heterogeneous expression in various tumors. 30 Disruption of lymphatic endothelial barrier integrity by upregulating the VE-cadherin phosphorylation expression level accelerated tumor cell migration into LV and promoted tumor metastasis. 33 In addition, collecting LV alter their gene signature during VEGF-D-driven metastasis tumors compared to nonmetastasis tumors. 34 These studies suggest diverse and dynamic gene signature in different types of tumors. 38 In a mouse inflammatory model, a subpopulation of CD11b + macrophages were involved in pathological lymphangiogenesis in the diaphragm. 39 Studies indicate that tumor lymphangiogenesis is also composed of heterogeneous cell subpopulations, showed that newly formed LV in LLC tumor models were mainly derived from pre-existing LEC; and 4 (iii) in a mouse model that lacks dermal LV (K14-VEGFR3-Ig mice), subcutaneous tumors failed to induce lymphangiogenesis, indicating that pre-existing LV are necessary for tumor-induced LV. 40 Such pre-existing LV-dependent tumor lymphangiogensis was validated in a prox1 genetic lineage tracing study. 35 However, several studies showed that de novo lymphangiogenesis also contributes to tumor lymphangiogenesis. For example, VEGFR-2 + or VEGFR-3 + BM cells were involved in lymphangiogenesis in subcutaneously inoculated fibrosarcoma. 41 In addition, BMderived podoplanin + cells were shown as LEPC to participate in lymphangiogenesis in subcutaneously inoculated melanoma. 42 Currently, the precise contribution of various LEC sources in tumor lymphangiogenesis remains incompletely understood.
| Lymphatic vessel structure
Taken together, such a wide range of heterogeneities collectively points to the functional complexity of lymphangiogenesis in tumor progression.
| FUNCTIONAL HETEROGENEITY OF TUMOR LYMPHANGIOGENESIS
Although it is well known that lymphangiogenesis both in primary tumors and draining LN promotes the spread of tumors, 43 the tumor context and the extent to which lymphangiogenesis contributes are unclear. Strikingly, a recent study using phylogenetic reconstruction methods showed that most colon cancer metastases in distant organs bypass LN in colon cancer. 44 Therefore, the findings on the functional heterogeneity and plasticity of tumor lymphangiogenesis should provide important insight into the role of lymphangiogenesis in tumor progression.
| Different functions of peritumoral and intratumoral lymphatic vessels
The function of LV in mediating tumor cell metastasis varies among LV in different locations within tumors. Strikingly, tumor cells prefer to utilize LV in the peritumoral area to metastasize rather than those in the deep area of tumor. 45 Thus, it is not difficult to infer that LV with normal open lumina in the tumor margin serve as the functional channels for tumor cell drainage, while the disorganized, destructed and collapsed LV in the deep area of tumor fail to facilitate tumor cell invasion and metastasis ( Figure 2 ). 10 Consistently, inhibition of peritumoral LV successfully reduced tumor metastasis, 46 while inhibition of intratumoral LV did not have significant effects on metastasis. 47 These studies suggest that peritumoral LV play an essential role in mediating the migration of tumor cells to LN and distant organs, and functional LV in the tumor margin should be targeted therapeutically. However, intratumor LV were reported to be associated with gastric tumor invasion, 48 suggesting that the intratumoral LV might be functional, even though this has not been commonly observed in other types of tumors.
| Active role in tumor metastasis
Lymphatic metastasis was thought to be a passive process in the past; however, accumulated evidence suggests that tumor LEC play active roles in mediating tumor cell invasion into LV and successful penetration into LN. 49 A study showed that LEC extensively formed filopodia toward VEGF-C producing tumor cells, facilitating tumor cell entry into the lymphatic vasculature. 3, 46 Another study demonstrated that LYVE-1-expressing LEC attracted hyaluronan-expressing cancer cells to invade into LV. 31 Notably, chemokines mediate LECinduced promotion of tumor cells homing to lymphatics. 50 For example, CXCL12-expressing LV promoted the invasiveness of various types of tumor cells in which CXCR4 was expressed. 51 Similarly, CCL21 production by LEC was reported to guide the CCR7 + cancer cells' migration to Niche roles in tumor progression to LV. 
| Niche roles in tumor progression
Previous studies suggest that newly induced LV in LN form a premetastasis lymphovascular niche in the LN even before the presence of tumor cells, which is regarded as a potential mediator of tumor metastasis to distant organs. [53] [54] [55] In addition, blood vessels in the LN also serve as an exit route for metastatic tumor cell dissemination. 56, 57 These findings suggest that premetastasis niches formed in the LN are important for tumor cell metastasis to LN or distant organs (Figure 2) . Interestingly, stem-like tumor cells (STC) were found in the vicinity of LV, suggesting that newly formed LV within tumors may serve as a niche for STC. 58, 59 Because the half- Peritumoral LV with open lumina are responsible for tumor cell invasion and facilitate further metastasis, while intratumoral LV, which appear to be compressed and collapsed, are regarded as nonfunctional for tumor cell metastasis. Tumor lymphangiogenesis occurs mostly via sprouting from pre-existing lymphatic endothelial cells (LEC), and, in some cases, lymphatic endothelial progenitor cells (LEPC) play a role. Besides, tumor-induced enlargement of collector LV and lymphangiogenesis in LN (serves as a "pre-metastatic" niche) promote tumor metastasis time of STC is long and are able to travel over long distances, which might be related to metastasis, it is tempting to speculate that the stem-like tumor cells trapped within the "lymphovascular" niche might be partly responsible for the tumor recurrence. So far, the molecular cues are not clear, but evidence shows that there is considerable crosstalk between the LEC and cancer stem cell. For example, in the B16F10 melanoma model, activated LEC secrete CXCL12 to attract a subpopulation of CXCR4-expressing stem-like melanoma cells. 58 In addition, another study indicated that expression of CCR7 promoted breast cancer progression by amplifying breast cancer STC. lymphangiogenesis has been reported to help tumors escape from immune response to facilitate tumor cell metastasis. 61 As mentioned previously, many tumors associated with metastasis, such as melanoma and breast cancer, express high levels of VEGF-C and contain a dense network of LV. 62, 63 An increase in VEGF-C expression in tumors is highly correlated with LN metastasis and poor prognosis in individuals with different tumor types, including skin, breast and lung cancers. Furthermore, LEC not only present antigens and modulate immune cell activation in physiology conditions 64, 65 but also promote tumor progression and metastasis by inhibiting the function of immune cells (Figure 3) . 40, 66 Mechanistically, VEGF-C plays an immunosuppressive role for LEC to scavenge and cross-present antigens for direct suppression of cytotoxic T lymphocytes. 61 LEC can also express immunosuppressive factors such as TGF-β and nitric oxide to maintain peripheral tolerance to self-antigens in lymph nodes by directly or indirectly regulating T-cell fate and function in immunity. 67 In addition, LEC can directly dampen DC maturation, in turn reducing their ability to activate effector T cells, and promote tumor tolerance. As we continue to elucidate the molecular mechanism for the structural heterogeneity and functional plasticity of tumor lymphangiogenesis, we hope to become increasingly capable of understanding the phenotypes of tumor lymphangiogenesis to inhibit tumor progression. Antilymphangiogenesis therapy may be more precise and effective when the factors involved in the structural and functional heterogeneity of dynamic lymphangiogenesis in tumor progression are sufficiently considered.
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